Upon completion of this educational activity, participants should be able to:
discuss current scientific data regarding the diagnosis and treatment of neurological disease;
discuss the pathogenesis and treatment of pain;
describe the basic science of brain function;
discuss new information regarding new drugs for commonly diagnosed neurological conditions and new uses for traditional drugs;
identify nonclinical issues of importance for the neurologist.
Relias Learning designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Relias Learning is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Neurology Alert’s editor in chief, Matthew Fink, MD, reports he is a consultant for Procter & Gamble. Peer reviewer M. Flint Beal, MD; executive editor Leslie Coplin; editor Jonathan Springston; and AHC Media Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.
You are not currently logged in.
To view content articles and access course testing and evaluation, please login or register now